
Global R&D Pipeline
My Favorite
Hot Targets:
5T4
Back
Total number of drugs
42
Phase II and later clinical stages
7.1%
Involving companies
39
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-5T4 nanobody (Novamab Biopharma) | Anti-5T4 nanobody (Novamab Biopharma) | Nanobody | Neoplasms Hemic and Lymphatic Diseases | Trophoblast glycoprotein inhibitors | Shanghai Novamab Biopharmaceuticals Co., Ltd. | Shanghai Novamab Biopharmaceuticals Co., Ltd. | Discovery | Discovery | Anti-5T4 nanobody (Novamab Biopharma) | detail > | |||||||||||
| Anatumomab mafenatox | Anatumomab mafenatox | Fab fragment | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Urogenital Diseases | Trophoblast glycoprotein inhibitors Tumor-associated glycoprotein 72 inhibitors | Active Biotech AB | Discontinued | Anatumomab mafenatox | detail > | |||||||||||||
| 5T4(Zonsen Peplib Biotech) | 5T4(Zonsen Peplib Biotech) | Peptide drug conjugates | Neoplasms | Trophoblast glycoprotein modulators | Zonsen Peplib Biotech Co., Ltd. | Discovery | Discovery | 5T4(Zonsen Peplib Biotech) | detail > | ||||||||||||
| ZV-0501 | ZV-0501 | Antibody drug conjugate (ADC) ADC | Neoplasms Endocrinology and Metabolic Disease Urogenital Diseases | Trophoblast glycoprotein inhibitors Tubulin inhibitors | Zhejiang Zova Biotherapeutics,Inc. | Zhejiang Zova Biotherapeutics,Inc. | Discovery | Discovery | MMAF Mafodotin | ZV-0501 | detail > | ||||||||||
| WO2024197151 | WO2024197151 | Bispecific antibody | Neoplasms | Salubris Biotherapeutics, Inc. | Salubris Biotherapeutics, Inc. | Discovery | WO2024197151 | detail > | |||||||||||||
| AVA-020 | AVA-020 | Recombinant protein | Neoplasms | Trophoblast glycoprotein modulators | Avacta Group Plc | Avacta Group Plc | Discovery | AVA-020 | detail > | ||||||||||||
| n501-SN38 | n501-SN38 | Antibody drug conjugate (ADC) ADC | Neoplasms | Trophoblast glycoprotein modulators DNA topoisomerase I inhibitors | Fudan University | Fudan University | Preclinical | Preclinical | CL2A | SN38 | n501-SN38 | detail > | |||||||||
| m603-MMAE | m603-MMAE | Antibody drug conjugate (ADC) ADC | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | Trophoblast glycoprotein inhibitors Tubulin inhibitors | Fudan University | Fudan University | Preclinical | Preclinical | MMAE 甲基澳瑞他汀E | m603-MMAE | detail > | ||||||||||
| MEDI-0641 | MEDI-0641 | Antibody drug conjugate (ADC) ADC | Neoplasms | Trophoblast glycoprotein inhibitors DNA inhibitors | MedImmune LLC | MedImmune LLC | Preclinical | Pyrrolobenzodiazepine | 2 | MEDI-0641 | cysteinyl 半胱氨酸 | detail > | |||||||||
| ChAdOx1 MVA 5T4 vaccine (Vaccitech) | ChAdOx1 MVA 5T4 vaccine (Vaccitech) | Therapeutic vaccine | Neoplasms Urogenital Diseases | Trophoblast glycoprotein inhibitors | Barinthus Biotherapeutics (UK) Ltd. | Phase 2 | ChAdOx1 MVA 5T4 vaccine (Vaccitech) | detail > |
Total 42 data
1
2
3
4
5


